Canary Center at Stanford

💡 Dr. Erin Grady shares a clear vision for advancing theranostics in practice: precision targeting drives effective treatment.

“If we can see it well, we can treat it well.”

💡 Dr. Corinne Beinat highlights the power of medicinal chemistry in designing stable peptide ligands for radiotherapeutics. Her lab’s [¹⁷⁷Lu]Lu-CMT2 targeting B7H3 shows improved binding affinity and tumor uptake in prostate cancer mice models for more precise targeted therapy

💡Dr. Christina Curtis’s “Big Bang Theory of Cancer” explains tumor evolution: many pre-malignant lesions are polyclonal, with identifiable high-risk subgroups.

Measure. Model. Predict.
Precision medicine must capture how tumors evolve, not just what they are.

💡Prostate cancer is one of most heritable cancers, presenting a unique and strong case for risk-stratified screening. Dr. Burcu Darst shares her lab’s findings that polygenic risk scores are highly predictive and work well across diverse populations.

💡 Lung cancer screening saves lives.

Dr. Natalie Liu, a thoracic surgeon, strongly advocates for early screening. Having cared for patients at the late stages, she’s seen firsthand what delayed detection costs. Expanding outreach and community awareness is essential.